Concepedia

Nicholas Fry

NF

Statistics

Publications

7

Citations

307

H-Index

7

Active since

2020

Affiliations

Supernus Pharmaceuticals (United States)(Current)

SUNY Upstate Medical University

Neuroscience Education Institute

Virginia Commonwealth University

CNS Healthcare

Nicholas Fry is an author at Supernus Pharmaceuticals (United States) specializing in pediatrics, psychopathology, and social sciences.

Top concepts

Publications per year

2020–2022

7

Publications

7

A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · Clinical Therapeutics · 2020 · 81 citations · Full text

Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · Clinical Therapeutics · 2021 · 53 citations

, , +11

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder

Azmi Nasser, Joseph T. Hull, Soumya A. Chaturvedi et al. · CNS Drugs · 2022 · 49 citations · Full text

A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · Journal of Clinical Psychopharmacology · 2021 · 40 citations · Full text

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · PubMed · 2021 · 36 citations · Full text

1–5 of 7